Edwards Lifesciences Corporation (EW) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $92.30 (-2.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 11, 2026 | Richard Newitter | Truist Financial | $89.00 | -3.6% |
| Feb 11, 2026 | David Roman | Goldman Sachs | $95.00 | +2.9% |
| Feb 4, 2026 | Danielle Antalffy | UBS | $94.00 | +1.8% |
| Jan 12, 2026 | Danielle Antalffy | UBS | $95.00 | +2.9% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $108.00 | +17.0% |
| Jan 7, 2026 | Rick Wise | Stifel Nicolaus | $105.00 | +13.8% |
| Dec 17, 2025 | William Plovanic | Canaccord Genuity | $87.00 | -5.7% |
| Dec 16, 2025 | David Rescott | Robert W. Baird | $87.00 | -5.7% |
| Dec 5, 2025 | Shagun Singh | RBC Capital | $100.00 | +8.3% |
| Dec 5, 2025 | David Rescott | Robert W. Baird | $88.00 | -4.7% |
| Dec 5, 2025 | William Plovanic | Canaccord Genuity | $89.00 | -3.6% |
| Dec 5, 2025 | Larry Biegelsen | Wells Fargo | $96.00 | +4.0% |
| Dec 5, 2025 | Rick Wise | Stifel Nicolaus | $100.00 | +8.3% |
| Dec 5, 2025 | Richard Newitter | Truist Financial | $92.00 | -0.3% |
| Dec 4, 2025 | Marie Thibault | BTIG | $103.00 | +11.6% |
| Nov 3, 2025 | Lee Hambright | Bernstein | $90.00 | -2.5% |
| Nov 3, 2025 | William Plovanic | Canaccord Genuity | $84.00 | -9.0% |
| Nov 3, 2025 | Jayson Bedford | Raymond James | $96.00 | +4.0% |
| Oct 31, 2025 | David Rescott | Robert W. Baird | $83.00 | -10.1% |
| Oct 29, 2025 | Matthew Taylor | Jefferies | $98.00 | +6.2% |
Top Analysts Covering EW
EW vs Sector & Market
| Metric | EW | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.08 | 2.25 | 2.41 |
| Analyst Count | 12 | 8 | 19 |
| Target Upside | +12.6% | +153002.0% | +21.5% |
| P/E Ratio | 50.44 | 3.42 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6.66B | $6.71B | $6.75B | 22 |
| 2027-03-31 | $1.74B | $1.76B | $1.78B | 11 |
| 2027-06-30 | $1.83B | $1.84B | $1.87B | 8 |
| 2027-09-30 | $1.84B | $1.85B | $1.88B | 8 |
| 2027-12-31 | $1.87B | $1.89B | $1.91B | 15 |
| 2028-03-31 | $1.93B | $1.95B | $1.97B | 10 |
| 2028-06-30 | $2.02B | $2.04B | $2.06B | 7 |
| 2028-09-30 | $2.03B | $2.04B | $2.07B | 7 |
| 2028-12-31 | $2.07B | $2.09B | $2.11B | 14 |
| 2029-12-31 | $8.81B | $8.93B | $9.06B | 11 |
| 2030-12-31 | $9.59B | $9.71B | $9.86B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.97 | $2.99 | $3.03 | 16 |
| 2027-03-31 | $0.80 | $0.81 | $0.82 | 10 |
| 2027-06-30 | $0.83 | $0.84 | $0.85 | 7 |
| 2027-09-30 | $0.84 | $0.85 | $0.86 | 7 |
| 2027-12-31 | $0.82 | $0.83 | $0.85 | 14 |
| 2028-03-31 | $0.89 | $0.91 | $0.92 | 11 |
| 2028-06-30 | $0.96 | $0.97 | $0.99 | 8 |
| 2028-09-30 | $0.95 | $0.96 | $0.98 | 8 |
| 2028-12-31 | $0.90 | $0.91 | $0.93 | 15 |
| 2029-12-31 | $4.14 | $4.21 | $4.29 | 4 |
| 2030-12-31 | $4.48 | $4.55 | $4.64 | 2 |
Frequently Asked Questions
What is the analyst consensus for EW?
The consensus among 12 analysts covering Edwards Lifesciences Corporation (EW) is Buy with an average price target of $101.70.
What is the highest price target for EW?
The highest price target for EW is $140.00, set by Matt Miksic at Credit Suisse on 2022-01-07.
What is the lowest price target for EW?
The lowest price target for EW is $66.00, set by William Plovanic at Canaccord Genuity on 2024-10-07.
How many analysts cover EW?
12 analysts have issued ratings for Edwards Lifesciences Corporation in the past 12 months.
Is EW a buy or sell right now?
Based on 12 analyst ratings, EW has a consensus rating of Buy (2.08/5) with a +12.6% upside to the consensus target of $101.70.
What are the earnings estimates for EW?
Analysts estimate EW will report EPS of $2.99 for the period ending 2026-12-31, with revenue estimated at $6.71B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.